Latest News Archive
Please select Category, Year, and then Month to display items
08 May 2024
Photo SUPPLIED
The Dean of the Faculty of Natural and Agricultural Sciences, Prof Paul Oberholster, has the pleasure of inviting you to the inaugural lecture of Prof Dirk Opperman.
Date: 21 May 2024
Time: 17:30
Venue: Equitas
Click here to RSVP before Wednesday, 15 May 2024. Alternatively, contact Christelle van Rooyen on +27 51 401 9190.
About Prof Dirk Opperman
Prof Dirk Opperman obtained his PhD in Biochemistry at the University of the Free State in 2008. This was followed by postdoctoral research on directed evolution with Prof Manfred T Reetz at the Max Planck Institute for Coal Research (Germany). In 2010, he was appointed in the Department of Microbiology and Biochemistry. He subsequently established structural biology at the UFS, and his current research focus lies at the interface of evolutionary and structure-function relationships of biocatalysts, and their application in green chemistry. He is an NRF B-rated researcher with co-authored papers in Science, Nature Communications, and Angewandte Chemie.
His research has been funded by both local and international organisations, ranging from industries such as SASOL to the Global Challenges Research Fund (GCRF, UK). He has a long-standing collaboration with researchers at the Delft University of Technology (TUDelft, the Netherlands) and is currently part of a European Research Area Network Cofund (ERA-NET Cofund) partnership on Food Systems and Climate (FOSC) that develops biocatalysts for upcycling waste.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004